Trial Profile
A multicentre, randomised, double-blind, tacrolimus dual therapy-controlled, parallel group, multiple oral dose study to evaluate the safety, tolerability, efficacy and pharmacokinetics of FK778 in liver transplant patients receiving standard tacrolimus (FK506) and steroids therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2007
Price :
$35
*
At a glance
- Drugs FK 778 (Primary)
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 24 Jun 2007 Results dat presented at ATC 2007 (1027726).
- 02 Jun 2007 New trial record.